drugset
drugset / Trial / NCT04764201

The Pharmacokinetic Characteristics and Safety Between HIP2001 and HGP2001 in Healthy Volunteers

NCT04764201 ↗

Phase 1 Completed 50 enrolled Hanmi Pharmaceutical Company Limited
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetic characteristics and safety between HIP2001 and HGP2001 in healthy volunteers.

Timeline

Start
2021-01-16
Primary completion
2021-02-26
Completion
2021-03-08

Drugs

EvaluationDrugModalityDoseRoute
Subject HGP2001 Unknown — —
Subject HIP2001 Unknown — —

Indications

atrial fibrillation